Equities

Sonendo Inc

SONX:QXR

Sonendo Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.0344
  • Today's Change0.000 / -0.29%
  • Shares traded95.75k
  • 1 Year change-95.81%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 18:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sonendo, Inc. is a commercial-stage medical technology company focused on saving teeth from tooth decay. The Company develops and manufactures the GentleWave System, a technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy, and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. Its Product segment includes the sales of the GentleWave System console and related accessories and instruments. The Company also offers ancillary products, such as SoundSeal and its Sonendo-branded liquid solution of ethylenediaminetetraacetic acid (EDTA). SoundSeal is a material used during the GentleWave Procedure to build and create a sealing platform on the top of the crown.

  • Revenue in USD (TTM)37.46m
  • Net income in USD-47.49m
  • Incorporated2006
  • Employees216.00
  • Location
    Sonendo Inc26061 Merit Circle, Suite 102LAGUNA HILLS 92653United StatesUSA
  • Phone+1 (949) 766-3636
  • Fax+1 (302) 636-5454
  • Websitehttps://sonendo.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
NanoVibronix Inc3.37m-2.82m1.92m10.00--0.6762--0.5696-1.32-1.321.501.020.70810.43112.05337,300.00-59.12-116.16-122.41-169.3664.5750.47-83.49-570.471.16-14.770.00--203.5948.3331.88---34.02--
BIOLASE Inc46.10m-36.19m2.01m157.00------0.0437-11.65-11.653.32-0.06361.312.558.73293,611.50-54.64-49.28-185.36-85.8033.0135.27-41.65-50.720.3589-6.001.19--1.451.27-30.39--18.63--
Avinger Inc7.43m-15.34m2.19m68.00--0.2361--0.2952-12.13-12.135.834.050.4341.238.03109,250.00-113.20-70.93-1,387.68-131.5719.9630.87-260.86-208.911.20-11.660.3428---7.51-0.673632.76---24.21--
Arch Therapeutics Inc148.17k-12.99m2.27m8.00------15.30-3.69-3.690.0383-2.830.100.0662--18,521.25-828.03-188.28---804.6339.58---8,276.08-26,945.920.0051-1.32----383.83---32.35---21.76--
Nuwellis Inc9.01m-22.81m2.35m59.00------0.261-181.60-181.6048.48-13.250.82921.527.30152,779.70-192.57-98.07-301.19-122.4860.2855.22-232.24-230.510.7119-1.52----3.7612.14-55.78--4.61--
Optimus Healthcare Services Inc1.89m-7.16m2.46m12.00------1.30-0.1744-0.17440.0454-0.18891.26--3.67157,291.70-477.28------85.93---379.51-----5.42----22.88---3.51------
Sonendo Inc37.46m-47.49m2.50m216.00--0.14--0.0668-0.5017-0.44360.39520.24530.4981.956.91173,421.30-63.14---78.26--35.04---126.79--1.73-8.540.5194--5.30---6.78------
Vycor Medical Inc1.36m-506.30k2.58m8.00------1.90-0.0155-0.01560.0417-0.10811.430.66945.08170,011.30-19.13-47.86----89.2389.60-13.38-35.420.0987-0.8001----19.43-0.654246.49---31.77--
SINTX Technologies Inc3.13m-8.60m2.59m43.00--0.2927--0.8271-271.52-271.5216.4411.820.18181.777.6372,697.67-50.01-45.71-62.67-57.3667.7258.47-275.14-681.801.79--0.0265--68.2994.2449.75--54.10--
Helius Medical Technologies Inc594.00k-8.84m2.61m22.00--0.4116--4.39-10.68-10.680.50421.980.06060.74864.4827,000.00-90.17-98.37-110.33-143.5712.7937.27-1,487.54-1,580.663.80--0.00---18.176.1437.11---41.95--
Invo Bioscience Inc5.77m-7.08m2.72m25.00------0.4706-3.24-3.242.440.35290.467712.0034.74230,781.20-57.44-94.63-116.03-151.4544.8974.91-122.80-343.110.2686-4.750.6588--267.3843.6226.24--87.09--
Heart Test Laboratories Inc18.60k-7.29m2.73m15.00--0.4568--146.82-5.65-5.650.00116.550.00350.0092--1,240.00-135.14---193.38--67.31---39,193.76--4.02-20.720.0777--261.17---3.95------
Acutus Medical Inc9.55m-9.70m2.97m233.00------0.3113-0.33010.09560.3261-0.13530.12111.141.4640,974.25-12.30-46.76-14.84-56.88-24.07-89.12-101.56-773.492.89-4.641.13--136.3627.03-141.35---35.99--
Tenon Medical Inc3.37m-13.87m3.09m21.00------0.9169-39.79-39.799.451.760.42522.275.27160,571.40-174.87---495.99--60.32---411.27--1.02--0.00--323.73--17.63------
ReShape Lifesciences Inc8.05m-9.02m3.29m31.00--1.08--0.4091-1.29-1.290.47660.10330.8820.80354.79259,548.40-98.88-136.06-169.55-194.3267.4756.30-112.11-408.360.8875--0.00---22.79-0.947475.36---49.29--
Data as of Sep 20 2024. Currency figures normalised to Sonendo Inc's reporting currency: US Dollar USD

Institutional shareholders

25.02%Per cent of shares held by top holders
HolderShares% Held
Pura Vida Investments LLCas of 31 Dec 20235.42m7.44%
First Light Asset Management LLCas of 30 Jun 20245.14m7.06%
Masters Capital Management LLCas of 31 Dec 20235.00m6.87%
Driehaus Capital Management LLCas of 31 Jan 20242.63m3.61%
Farther Finance Advisors LLCas of 30 Jun 202425.00k0.03%
WealthSource Partners LLCas of 31 Dec 20230.000.00%
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.